Skip to main content

ELND005 for Agitation and Aggression in Alzheimer's Disease

  • Completed

The purpose of this study is to determine whether the experimental drug ELND005 is effective in treating symptoms of agitation and aggression in people with Alzheimer's disease.

Minimum Age Maximum Age Gender Healthy Volunteers
50 Years 95 Years Both No
November 2012
May 2015
400
  • Diagnosis of probable Alzheimer's disease (MMSE score of 5 to 24 inclusive at screening)
  • Clinically significant agitation/aggression, defined as Neuropsychiatric Inventory (NPI) agitation/aggression subscore of ≥4, with a severity score of ≥2 at both screening and baseline visits
  • No response or suboptimal response to standard nonpharmacological interventions
  • Agitation/aggression attributable to medications, environmental conditions, or an active medical or psychiatric condition
  • Current diagnosis of major depressive disorder
  • Symptoms of psychosis (delusion or hallucinations) that require treatment with antipsychotics or psychiatric hospitalization
  • Treated with oral antipsychotic medications within 2 weeks prior to screening; treated with depot preparations of an antipsychotic within 3 months prior to screening
  • MRI scan abnormalities at screening that can be attributed to diseases or processes other than Alzheimer's disease

The experimental drug being tested in this Phase II study, ELDN005, is a small molecule that has been found to block the accumulation of beta-amyloid oligomers and possibly protect against cognitive decline. Known generically as scyllo-inositol, it is a naturally occurring plant sugar alcohol found in the coconut palm, oak bark, and other plants.

For more information about this trial or its study sites, please contact the Elan Call Center at 1-866-395-2121.

Name City State Zip Status Primary Contact
TransitionTIL Investigational Site Birmingham Alabama 35294 n/a

TransitionTIL Investigational Site Phoenix Arizona 85004 n/a

TransitionTIL Investigational Site Phoenix Arizona 85006 n/a

TransitionTIL Investigational Site Encino California 91316 n/a

TransitionTIL Investigational Site Escondido California 92025 n/a

TransitionTIL Investigational Site Fresno California 93710 n/a

TransitionTIL Investigational Site Irvine California 92697 n/a

TransitionTIL Investigational Site Long Beach California 90806 n/a

TransitionTIL Investigational Site Los Alamitos California 90720 n/a

TransitionTIL Investigational Site Los Angeles California 90073 n/a

TransitionTIL Investigational Site Newport Beach California 92663 n/a

TransitionTIL Investigational Site Santa Ana California 92701 n/a

TransitionTIL Investigational Site Norwalk Connecticut 06851 n/a

TransitionTIL Investigational Site Washington District of Columbia 20057 n/a

TransitionTIL Investigational Site Atlantis Florida 33462 n/a

TransitionTIL Investigational Site Deerfield Beach Florida 33064 n/a

TransitionTIL Investigational Site Delray Beach Florida 33445 n/a

TransitionTIL Investigational Site Lake Worth Florida 33449 n/a

TransitionTIL Investigational Site Miami Florida 33137 n/a

TransitionTIL Investigational Site Oakland Park Florida 33334 n/a

TransitionTIL Investigational Site Orlando Florida 32806 n/a

TransitionTIL Investigational Site Ormond Beach Florida 32174 n/a

TransitionTIL Investigational Site Port Charlotte Florida 33952 n/a

TransitionTIL Investigational Site Sarasota Florida 34243 n/a

TransitionTIL Investigational Site Sunrise Florida 33351 n/a

TransitionTIL Investigational Site Columbus Georgia 31909 n/a

TransitionTIL Investigational Site Savannah Georgia 31419 n/a

TransitionTIL Investigational Site Springfield Illinois 62702 n/a

TransitionTIL Investigational Site Bangor Maine 04402 n/a

TransitionTIL Investigational Site Easton Maryland 21601 n/a

TransitionTIL Investigational Site Winchester Massachusetts 01890 n/a

TransitionTIL Investigational Site Ann Arbor Michigan 48105 n/a

TransitionTIL Investigational Site Paw Paw Michigan 49079 n/a

TransitionTIL Investigational Site St. Paul Minnesota 55130 n/a

TransitionTIL Investigational Site Hattiesburg Mississippi 39401 n/a

TransitionTIL Investigational Site Stratford New Jersey 08084 n/a

TransitionTIL Investigational Site Rochester New York 14620 n/a

TransitionTIL Investigational Site Rochester New York 14623 n/a

TransitionTIL Investigational Site Charlotte North Carolina 28209 n/a

TransitionTIL Investigational Site Charlotte North Carolina 28211 n/a

TransitionTIL Investigational Site Durham North Carolina 27710 n/a

TransitionTIL Investigational Site Wilmington North Carolina 28401 n/a

TransitionTIL Investigational Site Winston-Salem North Carolina 27103 n/a

TransitionTIL Investigational Site Oklahoma City Oklahoma 73112 n/a

TransitionTIL Investigational Site Portland Oregon 97225 n/a

TransitionTIL Investigational Site Abington Pennsylvania 19001 n/a

TransitionTIL Investigational Site Jenkintown Pennsylvania 19046 n/a

TransitionTIL Investigational Site Norristown Pennsylvania 19401 n/a

TransitionTIL Investigational Site Philadelphia Pennsylvania 19104 n/a

TransitionTIL Investigational Site Philadelphia Pennsylvania 19107 n/a

TransitionTIL Investigational Site Pittsburgh Pennsylvania 15213 n/a

TransitionTIL Investigational Site North Charleston South Carolina 29406 n/a

TransitionTIL Investigational Site Port Royal South Carolina 29935 n/a

TransitionTIL Investigational Site Nashville Tennessee 37212 n/a

TransitionTIL Investigational Site DeSoto Texas 75115 n/a

TransitionTIL Investigational Site Richmond Virginia 23230 n/a

TransitionTIL Investigational Site Bellevue Washington 98007 n/a

TransitionTIL Investigational Site Calgary Alberta T2N-4Z6 n/a

TransitionTIL Investigational Site Kelowna British Columbia V1Y 3G8 n/a

TransitionTIL Investigational Site Toronto Ontario M4N 3M5 n/a

TransitionTIL Investigational Site Toronto Ontario M6M 3Z5 n/a

TransitionTIL Investigational Site Regina Saskatchewan S4T 1A5 n/a

Elan Pharmaceuticals

  • Elan Pharmaceuticals - Industry

Name Phone Extension Email
Elan Call Center 1-866-395-2121

A Prospective, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Efficacy and Safety Study of Oral ELND005 for Treatment of Agitation and Aggression in Patients With Moderate to Severe Alzheimer`s Disease